These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21921189)

  • 41. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.
    Scharf L; West AP; Gao H; Lee T; Scheid JF; Nussenzweig MC; Bjorkman PJ; Diskin R
    Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6049-54. PubMed ID: 23524883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement of antibody functionality by structure-guided paratope engraftment.
    Liu Q; Lai YT; Zhang P; Louder MK; Pegu A; Rawi R; Asokan M; Chen X; Shen CH; Chuang GY; Yang ES; Miao H; Wang Y; Fauci AS; Kwong PD; Mascola JR; Lusso P
    Nat Commun; 2019 Feb; 10(1):721. PubMed ID: 30760721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage.
    Zhou JO; Zaidi HA; Ton T; Fera D
    Front Immunol; 2020; 11():1529. PubMed ID: 32765530
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains.
    Fera D; Schmidt AG; Haynes BF; Gao F; Liao HX; Kepler TB; Harrison SC
    Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10275-80. PubMed ID: 24982157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
    Chen J; Kovacs JM; Peng H; Rits-Volloch S; Lu J; Park D; Zablowsky E; Seaman MS; Chen B
    Science; 2015 Jul; 349(6244):191-5. PubMed ID: 26113642
    [TBL] [Abstract][Full Text] [Related]  

  • 46. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.
    Chamat S; Nara P; Berquist L; Whalley A; Morrow WJ; Köhler H; Kang CY
    J Immunol; 1992 Jul; 149(2):649-54. PubMed ID: 1378074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure and design of broadly-neutralizing antibodies against HIV.
    Ryu SE; Hendrickson WA
    Mol Cells; 2012 Sep; 34(3):231-7. PubMed ID: 22736269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains.
    Wang S; Chan KW; Wei D; Ma X; Liu S; Hu G; Park S; Pan R; Gu Y; Nazzari AF; Olia AS; Xu K; Lin BC; Louder MK; McKee K; Doria-Rose NA; Montefiori D; Seaman MS; Zhou T; Kwong PD; Arthos J; Kong XP; Lu S
    Nat Commun; 2024 May; 15(1):4301. PubMed ID: 38773089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.
    Liang Y; Guttman M; Davenport TM; Hu SL; Lee KK
    Biochemistry; 2016 Apr; 55(15):2197-213. PubMed ID: 27003615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity.
    Pantophlet R; Trattnig N; Murrell S; Lu N; Chau D; Rempel C; Wilson IA; Kosma P
    Nat Commun; 2017 Nov; 8(1):1601. PubMed ID: 29150603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody.
    Bonsignori M; Zhou T; Sheng Z; Chen L; Gao F; Joyce MG; Ozorowski G; Chuang GY; Schramm CA; Wiehe K; Alam SM; Bradley T; Gladden MA; Hwang KK; Iyengar S; Kumar A; Lu X; Luo K; Mangiapani MC; Parks RJ; Song H; Acharya P; Bailer RT; Cao A; Druz A; Georgiev IS; Kwon YD; Louder MK; Zhang B; Zheng A; Hill BJ; Kong R; Soto C; ; Mullikin JC; Douek DC; Montefiori DC; Moody MA; Shaw GM; Hahn BH; Kelsoe G; Hraber PT; Korber BT; Boyd SD; Fire AZ; Kepler TB; Shapiro L; Ward AB; Mascola JR; Liao HX; Kwong PD; Haynes BF
    Cell; 2016 Apr; 165(2):449-63. PubMed ID: 26949186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of a remote mutation from the contact paratope on the structure of CDR-H3 in the anti-HIV neutralizing antibody PG16.
    Kondo HX; Kiribayashi R; Kuroda D; Kohda J; Kugimiya A; Nakano Y; Tsumoto K; Takano Y
    Sci Rep; 2019 Dec; 9(1):19840. PubMed ID: 31882602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody recognition of HIV and dengue glycoproteins.
    Krauss IJ
    Glycobiology; 2016 Aug; 26(8):813-9. PubMed ID: 26941393
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder.
    Uversky VN
    Arch Virol; 2021 May; 166(5):1283-1296. PubMed ID: 33606110
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structural evolution of glycan recognition by a family of potent HIV antibodies.
    Garces F; Sok D; Kong L; McBride R; Kim HJ; Saye-Francisco KF; Julien JP; Hua Y; Cupo A; Moore JP; Paulson JC; Ward AB; Burton DR; Wilson IA
    Cell; 2014 Sep; 159(1):69-79. PubMed ID: 25259921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.
    Liao HX; Bonsignori M; Alam SM; McLellan JS; Tomaras GD; Moody MA; Kozink DM; Hwang KK; Chen X; Tsao CY; Liu P; Lu X; Parks RJ; Montefiori DC; Ferrari G; Pollara J; Rao M; Peachman KK; Santra S; Letvin NL; Karasavvas N; Yang ZY; Dai K; Pancera M; Gorman J; Wiehe K; Nicely NI; Rerks-Ngarm S; Nitayaphan S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Sinangil F; Kim JH; Michael NL; Kepler TB; Kwong PD; Mascola JR; Nabel GJ; Pinter A; Zolla-Pazner S; Haynes BF
    Immunity; 2013 Jan; 38(1):176-86. PubMed ID: 23313589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human immunodeficiency virus: refolding the envelope.
    Kwong PD
    Nature; 2005 Feb; 433(7028):815-6. PubMed ID: 15729327
    [No Abstract]   [Full Text] [Related]  

  • 60. Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies.
    Pujanauski LM; Janoff EN; McCarter MD; Pelanda R; Torres RM
    Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1422-7. PubMed ID: 23288906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.